Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   11/09/2026
5,290 USD (+0,95%)
(+0,95%)   11/09/2026

31 augustus 2026 · Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations · Persbericht

27 augustus 2026 · Alvotech to present at upcoming investor conferences in September · Persbericht

21 augustus 2026 · Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets · Persbericht

19 augustus 2026 · Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update · Persbericht

10 augustus 2026 · Alvotech to Report Financial Results for H1 2026 · Persbericht

29 juli 2026 · Alvotech announces successful closure of FDA inspection of manufacturing facility · Persbericht

3 juli 2026 · Transactions of Managers and Closely Associated Persons · Persbericht

1 juli 2026 · Alvotech further strengthens liquidity by securing term loan facility of $75 million · Persbericht

23 juni 2026 · Transactions of Managers and Closely Associated Persons · Persbericht

18 juni 2026 · Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement · Persbericht

16 juni 2026 · Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement · Persbericht

15 juni 2026 · Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares · Persbericht

10 juni 2026 · Transactions of Managers and Closely Associated Persons · Persbericht

8 juni 2026 · Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® · Persbericht

4 juni 2026 · Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® · Persbericht

3 juni 2026 · Main Results of 2026 Annual and Extraordinary General Meeting · Persbericht

2 juni 2026 · Alvotech to present at upcoming investor conferences in June · Persbericht

1 juni 2026 · Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland · Persbericht

11 mei 2026 · Alvotech announces completion of FDA surveillance inspection at Reykjavik facility · Persbericht

6 mei 2026 · Alvotech Q1 2026 Financial Results · Persbericht

Mijn selecties